# Goal Oriented Strategy to Preserve Ejection Fraction Trial

> **NCT03236818** · PHASE4 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 30 (estimated)

## Conditions studied

- Pulmonary Arterial Hypertension

## Interventions

- **DRUG:** ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)

## Key facts

- **NCT ID:** NCT03236818
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-05
- **Primary completion:** 2017-09
- **Final completion:** 2017-09
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2017-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03236818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03236818, "Goal Oriented Strategy to Preserve Ejection Fraction Trial". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03236818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*